Uncovering the Truth In Trasylol

When a drug hits the market that is described as a success -- it is not too often that those in the medical profession turn against use of the drug and boycott it's sale. This is exactly what happened with Trasylol Aprotinin, an injectable drug that controls blood in individuals undergoing heart surgery. Reports of the drugs side effects, which included stroke, heart attack and death, surfaced; and like a rock dropping into a lake, the dangers of Trasylol rippled throughout the medical community.

The New England Journal of Medicine study published in 2006 reported that after being administered Trasylol-Aprotinin, patients risk of renal failure, stroke, death and heart attack increased by 259 percent; at that point the drug had already been manufactured by Bayer AG for 13 years, since 1993.

Singing Its Praises

Ironically, the drug had been mentioned in The Washington Post in early January 2006 as an example of a drug so safe that it no longer required clinical study. The article stated that Trasylol dropped the risk of blood transfusions in bypass patients by one-third and that after only 12 of 64 clinical studies, its advantages were clear. The article also included information that suggested if scientists had used the previous results of the drug, which were positive, then additional clinical trials would not have been necessary.

Tides Turn for Trasylol

The above article ran on January 2, 2006. However, once the New England Journal of Medicine study on Trasylol-Aprotinin was published on the risks of approximately 1,000 heart surgery patients, the drug's use began to diminish. Once the study was published, the U.S. Food and Drug Administration (FDA) began investigating the alleged side effects and, even after protests by Bayer officials claiming the results of the study were inaccurate, the FDA began discouraging the use of Trasylol-Aprotinin among patients.

Though Bayer has tried to discredit this study and market the drug for other procedures (including hip replacement surgery), lawsuits have begun to flow in as more and more patients have been found who have experienced detrimental side effects from the use of Trasylol-Aprotinin in their heart surgeries.

Have You Suffered Side Effects?

If you or a loved one have suffered side effects, such as stroke, heart attack, encephalopathy or even death, after the use of Trasylol-Aprotinin in a surgical heart procedure, you may be eligible for compensation and damages for your lost wages, medical care, future medical care, loss of consort, and/or emotional and physical pain and suffering. Contact an experienced pharmaceutical attorney who can help you evaluate your claim and attain the compensation you deserve.

Article Source: http://www.a1-articledirectory.com

LegalView offers additional resources on Trasylol-Aprotinin lawsuits and litigation at its information portal, trasylol-aprotinin.legalview.com/. Also use LegalView's vast array of legal topics to learn about the most controversial prescription drugs on the market such as Vytorin and Zetia or learn about the one of the newer practice areas found at baxter-heparin.legalview.com, which discusses Baxter Heparin's side effects.

Please Rate this Article

5 out of 54 out of 53 out of 52 out of 51 out of 5 

Not yet Rated